FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase ...
Nasdaq

Corvus Pharmaceuticals Reports Interim Data from Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals announced new interim results from its Phase 1 clinical trial of soquelitinib in patients with moderate to severe atopic dermatitis. The randomized, double-blind, ...
Everyday Health

Atopic Dermatitis Medications: Topical Steroids and Other Types to Know

There is no cure for atopic dermatitis, the most common form of eczema. Instead, treatment can help reduce symptoms and establish long-lasting disease control. While atopic dermatitis treatment plans ...
Yahoo Finance

Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline

Dublin, April 10, 2026 (GLOBE NEWSWIRE)-- The "Atopic Dermatitis: Seven-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering. This report ...
Business Wire

Dermavant Announces Highly Favorable Results from Pediatric Maximal Usage Study of VTAMA® (tapinarof) cream, 1% in Atopic Dermatitis

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, ...